



LKT Laboratories, Inc.

VGX-1027

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

## Product Information

Product ID V2792

CAS No. 6501-72-0

### Chemical Name

Synonym GIT27

Formula  $C_{11}H_{11}NO_3$

Formula Wt. 205.21

### Melting Point


Purity  $\geq 98\%$

Solubility DMSO:  $\geq 56$  mg/mL

Store Temp  $-20^{\circ}C$

Ship Temp Ambient

**Description** VGX-1027 displays immunomodulatory and anti-inflammatory activities by inhibiting toll-like receptor 4 (TLR4) signaling. In diabetic mice, VGX-1027 decreases synthesis of pro-inflammatory cytokines and improves glomerulosclerosis. In other animal models, this compound inhibits antigen presentation, preventing the development of systemic lupus erythmatosus (SLE), increases survival rates and improving overall pathology.



## Pricing and Availability

*Bulk quantities available upon request*

Product ID	Size	List Price
V2792	5 mg	\$66.90
V2792	10 mg	\$113.90
V2792	50 mg	\$445.90

**References** Fagone P, Muthumani K, Mangano K, et al. VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. *Immunology*. 2014 Aug;142(4):594-602. PMID: 24527796.

Cha JJ, Hyun YY, Lee MH, et al. Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. *Endocrinology*. 2013 Jun;154(6):2144-55. PMID: 23568555.

Stojanovic I, Cuzzocrea S, Mangano K, et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. *Clin Immunol*. 2007 Jun;123(3):311-23. PMID: 17449326.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.